-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAVO-412 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAVO-412 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAVO-412 in Solid Tumor Drug Details: TAVO-412 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rose Bengal Sodium in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rose Bengal Sodium in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rose Bengal Sodium in Metastatic Ovarian Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Tislelizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-10 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-10 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-10 in Atopic Dermatitis (Atopic Eczema) Drug Details: PH-10 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-10 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-10 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-10 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: PH-10 is...
-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
NewTesticular Cancer – Drugs In Development, 2024
Empower your strategies with our Testicular Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Testicular cancer stands out as a prevalent malignancy affecting men in the age group of 15 to 45 years. Its etiology is complex, involving a combination of genetic and environmental factors. Advancements in understanding the epidemiology, pathophysiology, and diagnostic approaches have paved the way for sophisticated management strategies. Notably, the prognosis for testicular cancer has significantly improved, boasting cure rates reaching up...
-
Product Insights
NewEwing Sarcoma – Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...